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Background: Inflammatory bowel diseases (IBD) are chronic diseases of the gastrointestinal tract. Although their
pathogenesis is unclear, the combination of genetic predisposition and environmental components are believed to
be the main cause of these diseases. Recently, many variants in interleukin 23 receptor (IL23R) and autophagy-related
16-like 1 (ATG16L1) genes have been associated with the disease. Our objective was to assess the frequency of ATG16L1
(T300A) and IL23R (L310P) variants in Moroccan IBD (Crohn’s disease and Ulcerative Colitis) patients and to evaluate a
possible effect of these variants on disease’s phenotype and clinical course.
Methods: 96 Moroccan IBD patients and 114 unrelated volunteers were genotyped for ATG16L1 (T300A) and IL23R
(L310P) variants by PCR-restriction fragment length polymorphism.
Results: This is the first report on the prevalence of ATG16L1 (T300A) and IL23R (L310P) variants in a Moroccan group.
We found that IL23R (L310P) variant conferred a protective effect for crohn’s disease (CD) but not ulcerative colitis (UC)
patients. The presence of ATG16L1 (T300A) mutated alleles was associated with CD type but not with disease onset. In
addition, the carriage of T300A variant alleles conferred a protective effect in UC.
Conclusion: Our results showed that the prevalence of ATG16L1 and IL23R variants was not significantly different
between patients and controls. However a possible role of ATG16L1 (T300A) on CD phenotype was suggested.
Keywords: IBD, ATG16L1, IL23R, Moroccan populationBackground
Inflammatory bowel disease (IBD) is a chronic and multi-
factorial disease of the gastrointestinal tract. It includes
Crohn’s disease (CD), ulcerative colitis (UC) and undeter-
mined colitis. Their etiologies remain complex and unclear
involving an inadequately defined relationship between mi-
crobial insult, genetic predisposition and altered intestinal
barrier permeability [1]. Several genetic studies have
attempted to find out more about the molecular pathogen-
esis of CD and UC.
Genetic variations in genes related to innate and adap-
tive immunity have been implicated in IBD pathogenesis.
Positive correlations were reported for Interleukin 23* Correspondence: nadiaserbati@yahoo.fr
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unless otherwise stated.receptor (IL23R) [2] and Autophagy related 16-like 1
(ATG16L1) [3,4] genes.
IL-23 is a heterodimeric cytokine produced by acti-
vated macrophages and dendritic cells. It consists of two
subunits, a p40 subunit, shared with the IL-12, and a
specific IL-23 subunit called p19 [5,6]. Studies have shown
that IL-23 is involved in the initiation of the innate and
adaptive immune activation that characterizes IBD. It
binds a complex of IL-23R and IL-12Rβ subunits. IL-23R
is predominantly expressed on activated/memory T cells,
T-cell clones, natural killer’s (NK) cells and, at low levels,
in monocytes, macrophages, and dendritic cell populations
[7,8]. Recent studies have shown the association of some
single nucleotide polymorphisms (SNPs) in the IL-23R
gene with chronic inflammatory diseases especially IBD
(CD and UC). The variant L310P of IL23R gene (more fre-
quent in controls) was reported to confer a strong protec-
tion against CD [2]. In Ulcerative colitis, the effect of this
mutation seems to be insignificant [9]. In addition, Lin ZLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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polymorphism in UC females [10].
Several studies have established an association be-
tween ATG16L1 and IBD in various populations. The
ATG16L1 gene plays a key role in autophagy pathways.
It encodes a protein widely expressed in intestinal epi-
thelial cells, lymphocytes and macrophages and mediates
resistance to intracellular pathogens such as bacteria and
viral particles [11]. Hampe at al. reported an association
between the T300A (c898G > A) polymorphism and
Crohn’s disease [3]. Subsequent replication studies re-
vealed divergent results.
No data were available on the frequency of the ATG16L1
and IL23R variants in the Moroccan population. Hence,
we aimed to examine the association between IL23R
(L310P) and ATG16L1 (T300A) polymorphisms and in-
flammatory bowel disease (Crohn’s disease and Ulcerative
colitis) in a cohort of Moroccan patients.Methods
Patients and controls
In this study, a group of 96 Moroccan unrelated IBD pa-
tients were recruited at the gastroenterology department
of Averroes Hospital, Casablanca, Morocco. The control
group included 114 unrelated Moroccan volunteers (blood
donors) with no discernable symptoms suggestive of IBD.
The diagnosis of CD or UC was based on established clin-
ical, radiological, endoscopic, and histopathology criteria.
Demographic and clinical characteristics were ob-
tained from the participants through a detailed question-
naire. CD phenotype was stratified by age at diagnosis,
location and disease’s behaviour according to the Mon-
treal classification [12].
For UC patients, anatomic location was subgrouped
using the Paris classification as being ulcerative proctitis
(E1), left-sided UC (E2), and extensive UC (E3) [13].
Differences in the frequency of disease characteristics
such as age at diagnosis, gender, extra-intestinal manifes-
tations, similar familial cases, and antecedents like ap-
pendectomy and smoking were also assessed. The study
was approved by the medical school of Casablanca ethical
committee. A written informed consent was obtained
from all participants or their guardians. Both IBD patients
and control group are originated from the different re-
gions of Morocco and confirmed the Moroccan origin of
their parents and grandparents.Genotyping methods
Genomic DNA was isolated from whole blood samples by
salting-out method [6]. DNA amount and quality were
measured by spectrophotometry. IL23R and ATG16L1 var-
iants genotyping was performed using polymerase chain
reaction (PCR) restriction fragment length polymorphismanalysis (RFLP) as described respectively by Lin et al. and
Csöngei et al. [10,14].
Reactions were performed in a final volume of 25 μl.
PCR products were cleaved with Hph I (L310P) and Lwe
I (T300A) (New England Biolabs Ipswich, UK) and elec-
trophored on a 3% agarose gel in the presence of a mo-
lecular weight marker ladder 100 (New England Biolabs
Ipswich, UK). After staining with ethidium bromide,
Ultraviolet was used on a transilluminator for reading
the gel.
Statistical analysis
Statistical analysis was performed using MedCalc statis-
tical software version 11.6. The Hardy-Weinberg equilib-
rium test was performed separately for patients and
controls to measure the distribution of polymorphisms.
The association between IBD (CD and UC) and IL23R
(L301P) ATG16L1 (T300A) genotypes was determined
by Fisher's exact test (Odds Ratio with Confidence inter-
val (CI) at 95%). The χ2 test or Fisher test was used to
correlate the IL23R and ATG16L1 polymorphisms and
clinical parameters. The P value (<0.05) was considered
statistically significant in all variables.
Results
Epidemiologic data
One hundred fourteen participants from the general
population were genotyped for ATG16L1 (T300A) and
IL23R (L310P) along with 69 Crohn’s disease patients
(25 women and 44 men) and 30 UC patients (14 women
and 16 men). The average age of diagnosis was 24.17 ±
2.48 for CD patients and 35.37 ± 5 for UC patients. For
control group, epidemiological and clinical data are
shown in Additional file 1: Table S1.
Genetic and clinical correlations
Statistical analysis of the distribution of SNPs studied
showed that allele frequencies were conformed to
Hardy–Weinberg expectations (=1.14, P = 0.57; =0.017,
P = 0.99) (=0.03, P = 0.86; =0.017, P = 0.99) for T300A
(ATG16L1) and L310P (IL23R) in CD patients and con-
trols respectively.
Correlation between demographic and clinical charac-
teristics according to ATG16L1 and IL23R genotypes
(Tables 1 and 2) revealed a positive association between
CD Type and ATG16L1 polymorphism (T300A) with
P = 0.03 (Table 1). However, no genotype-phenotype
correlation was noticed for the IL23R SNP.
Case–control studies were carried out for the selected
polymorphisms. The genotypic and allelic frequencies
for the T300A and L310P polymorphisms are presented
in Tables 3 and 4 respectively.
The non-synonymous polymorphism, rs2241880 (Thr
300Ala), located on the ATG16L1 gene, showed no
Table 1 Genotypic frequencies according to clinical parameters of the Moroccan CD patients investigated for the
T300A polymorphism
ATG16L1 T300A P value Chi-square
N AA AG GG Test
Age of onset 69 0.37 4.30
<17 years 10 - 8 (80.0) 2 (20.0)
17-40 52 15 (28.8) 30 (57.7) 7 (13.5)
>40 years 7 1 (14.3) 5 (71.4) 1 (14.3)
Sex 69 0.57 1.14
Woman 25 4 (16.0) 17 (68.0) 4 (16.0)
Man 44 12 (27.3) 26 (59.1) 6 (13.6)
Type 69 0.03 13.7
Fistulizing 26 5 (19.2) 20 (76.9) 1 (3.8)
Non fistulizing Non stenosing 24 7 (29.2) 10 (41.7) 7 (29.2)
Stenosing 12 4 (33.3) 8 (66.7) -
Fistulizingstenosing 7 - 5 (71.4) 2 (28.6)
Localization 69 0.36 17.4
L1 19 1 (5.3) 13 (68.4) 5 (26.3)
L1 + P 2 1 (50.0) 1 (50.0) -
L2 10 4 (40.0) 4 (40.0) 2 (20.0)
L2 + P 7 3 (42.9) 4 (57.1) -
L3 19 6 (31.6) 11 (57.9) 2 (10.5)
L3 + P 1 - 1 (100.0) -
L4 2 - 1 (50.0) 1 (50.0)
L4 + L2 4 1 (25.0) 3 (75.0) -
P 5 - 5 (100.0) -
SFC 69 0.09 4.8
Presence 4 - 2 (50.0) 2 (50.0)
Absence 65 16 (24.6) 41 (63.1) 8 (12.3)
Smoking 69 0.96 0.1
Presence 28 7 (25.0) 17 (60.7) 4 (14.3)
Absence 41 9 (22.0) 26 (63.4) 6 (14.6)
Appendectomy 69 0.22 3.1
Presence 9 2 (22.2) 4 (44.4) 3 (33.3)
Absence 60 14 (23.3) 39 (65.0) 7 (11.7)
EIM 69 0.97 0.1
Presence 39 9 (23.1) 24 (61.5) 6 (15.4)
Absence 30 7 (23.3) 19 (63.3) 4 (13.3)
Surgery 69 0.14 4.0
Presence 29 4 (13.8) 22 (75.9) 3 (10.3)
Absence 40 12 (30.0) 21 (52.5) 7 (17.5)
(SFC: Similar familial cases; EIM: Extra intestinal manifestations; N: Total number; AA: wild type ATG16L1 T300A, AG: ATG16L1 T300A heterozygous variant, GG:
ATG16L1 T300A homozygous variant).
Serbati et al. BMC Research Notes 2014, 7:570 Page 3 of 8
http://www.biomedcentral.com/1756-0500/7/570significantly increased risk of CD among individuals carry-
ing GG genotype or G allele with the respective odds ratio
2.08 (CI: 0.70-6.17, P = 0.19); 1.22 (CI: 0.79-1.86, P = 0.36)
(Table 5). In addition, individuals carrying the mutatedallele are not protected from the disease. In contrast to the
L310P polymorphism in IL23R gene, which confers protec-
tion to individuals with the TTgenotype and Tallele against
the development of Crohn’s disease, with respective odds
Table 2 Genotypic frequencies according to clinical parameters of the Moroccan CD patients investigated for the
L310P polymorphism
IL23R L310P P value Chi-square
N CC CT TT Test
Age of onset 69 0.16 3.7
<17 years 10 6 (60.0) 4 (40.0)
17-40 52 40 (76.9) 12 (23.1)
>40 years 7 7 (100.0)
Sex 69 0.86 0.0
Woman 25 19 (76.0) 6 (24.0)
Man 44 34 (77.3) 10 (22.7)
Type 69 0.11 6.1
Fistulizing 26 20 (76.9) 6 (23.1)
Non fistulizing Non stenosing 24 21 (87.5) 3 (12.5)
Stenosing 12 9 (75.0) 3 (25.0)
Fistulizingstenosing 7 3 (42.9) 4 (57.1)
Localization 69 0.29 9.6
L1 19 16 (84.2) 3 (15.8)
L1 + P 2 2 (100.0) -
L2 10 6 (60.0) 4 (40.0)
L2 + P 7 7 (100.0) -
L3 19 13 (68.4) 6 (31.6)
L3 + P 1 - 1 (100.0)
L4 2 2 -
L4 + L2 4 3 (75.0) 1 (25.0)
P 5 4 (80.0) 1 (20.0)
SFC 69 0.60 0.3
Presence 4 4 (100.0) -
Absence 65 49 (75.4) 16 (24.6)
Smoking 69 1.0 0.0
Presence 28 22 (78.6) 6 (21.4)
Absence 41 31 (75.6) 10 (24.4)
Appendectomy 69 0.73 0.12
Presence 9 6 (66.7) 3 (33.3)
Absence 60 47 (78.3) 13 (21.7)
EIM 69 0.14 2.14
Presence 39 33 (84.6) 6 (15.4)
Absence 30 20 (66.7) 10 (33.3)
Surgery 69 0.30 1.1
Presence 29 20 (69.0) 9 (31.0)
Absence 40 33 (82.5) 7 (17.5)
(SFC: Similar familial cases; EIM: Extra intestinal manifestations; N: Total number; CC: wild type IL23R L310P, CT: IL23R L310P heterozygous variant, TT: IL23R
L310P homozygous variant).
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P = 0.48) (Table 4).
Additionally, our study assessed the association of
ATG16L1 (T300A) and IL23R (L310P) polymorphisms withUC. Analysis of distribution of the two polymorphisms
showed that allele frequencies were in Hardy-Weinberg
equilibrium (=1.76, P = 0.41 and =0.017, P = 0.99) for
ATG16L1 and IL23R (=2.9, P = 0.23; =0.017, P = 0.99).
Table 3 Genotypic and allelic frequencies for the
ATG16L1 of CD patients and controls




OR (0.95 CI) P value
AA 16 (23.2) 30 (26.1) 1.0
AG 43 (62.3) 76 (66.1) 1.06 (0.52-2.16) 0.87
GG 10 (14.5) 9 (7.8) 2.08 (0.70-6.17) 0.19
A 75 (54.3) 136 (59.1) 1.0
G 63 (45.7) 94 (40.9) 1.22 (0.79-1.86) 0.36
(AA: wild type ATG16L1 T300A, AG: ATG16L1 T300A heterozygous variant, GG:
ATG16L1 T300A homozygous variant; N: Total number; OR: odd ratio; CI
confidence interval; P: (P < 0.05)).
Table 5 Genotypic frequencies according to clinical








Age of onset 30 0.12 4.32
<17 years -
17-40 21 10 (47.6) 8 (38.1) 3 (14.3)
>40 years 9 1 (11.1) 7 (77.8) 1 (11.1)
Sex 30 0.41 1.76
Woman 14 4 (28.6) 7 (50.0) 3 (21.4)
Man 16 7 (43.8) 8 (50.0) 1 (6.3)
Localization 30 0.71 3.73
Leftcolitis 11 5 (45.5) 5 (45.5) 1 (9.1)
Extensive colitis 2 - 2 (100.0) -
Pancolitis 13 4 (30.8) 7 (53.8) 2 (15.4)
Proctitis 4 2 (50.0) 1 (25.0) 1 (25.0)
SFC 30 0.41 1.79
Presence 1 1 (100.0) - -
Absence 29 10 (34.5) 15 (51.7) 4 (13.8)
Smoking 30 0.19 3.36
Presence 8 5 (62.5) 2 (25.0) 1 (12.5)
Absence 22 6 (27. 3) 13 (59.1) 3 (13.6)
Appendectomy 30 0.05 6.20
Presence - - - -
Absence 30 11 (36.7) 15 (50.0) 4 (13.3)
EIM 30 0.50 1.38
Presence 17 7 (41.2) 7 (41.2) 3 (17.6)
Absence 13 4 (30.8) 8 (61.5) 1 (7.7)
Surgery 30 0.22 3.04
Presence 4 3 (75.0) 1 (25.0) -
Absence 26 8 (30.8) 14 (53.8) 4 (15.4)
(SFC: Similar familial cases; EIM: Extra intestinal manifestations; N: Total
number; AA: wild type ATG16L1 T300A, AG: ATG16L1 T300A heterozygous
variant, GG: ATG16L1 T300A homozygous variant).
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relation was observed in UC (Tables 5 and 6).
The genotypic and allelic frequencies did not signifi-
cantly differ between UC patients and healthy controls
for the two polymorphisms (Tables 7 and 8).
Carriers of mutated allele in ATG16L1 gene have a
protective effect for UC, with an odds ratio of 0.90 (CI:
0.50-1.61, P = 0.72) (Table 7). While carriers of mutated
allele in IL23R gene are not protected from UC, with an
OR of 2.10 (CI: 0.92-4.77, P = 0.08) (Table 8).
Discussion
ATG16L1polymorphism
The association of genes within the autophagy pathway
with IBD was observed in several studies. One of the
prime candidate genes discovered was the ATG16L1 gene,
ATG16L1 is a protein expressed in the colon, leukocytes,
intestinal epithelial cells, small intestine, and spleen [15].
A mutation on the gene encoding this protein, located on
chromosome 2, has been associated with the onset of ileal
CD [16]. It has been shown that ATG16L is a key mol-
ecule in elucidating the genetic aspects of CD. The find-
ings of associations with variants in ATG16L1 and IBD
have prompted further research on understanding the role
of the autophagy pathway in disease pathogenesis.
During a genome-wide survey of 19 779 non-synonymous
single nucleotide polymorphisms, the (Thr300Ala) variant,
located at the N terminus of the WD-repeat domain inTable 4 Genotypic and allelic frequencies for the IL23R of
CD patients and controls




OR (95% CI) P value
CC 53 (76.8) 98 (85.2) 1.0
CT 8 (23.2) 14 (12.2) 1.06 (0.41-2.68) 0.91
TT 0.0 3 (2.6) 0.26 (0.01-5.19) 0.38
C 114 (82.6) 210 (91.3) 1.0
T 8 (17.4) 20 (8.7) 0.74 (0.31-1.73) 0.48
CC: wild type IL23R L310P, CT: IL23R L310P heterozygous variant, TT: IL23R
L310P homozygous variant; N: Total number; OR: odd ratio; CI confidence
interval; P: (P < 0.05).ATG16L1, was found to be highly associated with CD by
using a haplotype and regression analysis [3]. Subsequent to
the initial genome wide association study, many studies have
consistently identified associations between the ATG16L1
(Thr300Ala) variant and CD [17,18]. This finding has been
widely replicated in different populations [19-32].
In the present study, we examined the association of
ATG16L1 (T300A) genetic variant with CD and UC in
Moroccan patients and controls. Upon association ana-
lysis, we were not able to establish a significant effect on
CD risk in Moroccan IBD cohort. Our result was in con-
cordance with the lack of association reported in a repli-
cation study performed in Japan [33]. In addition, Van
Limbergen et al. [34] observed that the ATG16L1 variant
Table 6 Genotypic frequencies according to clinical








Age of onset 30 0.31 2.34
<17 years - - - -
17-40 21 16 (76.2) 4 (19.0) 1 (4.8)
>40 years 9 5 (55.6) 4 (44.4) -
Sex 30 0.30 2.93
Woman 14 11 (78.6) 2 (14.3) 1 (7.1)
Man 16 10 (62.5) 6 (37.5) -
Localization 30 0.43 5.95
Leftcolitis 11 6 (54.5) 5 (45.5) -
Extensive colitis 2 1 (50.0) 1 (50.0) -
Pancolitis 13 10 (76.9) 2 (15.4) 1 (7.7)
Proctitis 4 4 (100.0) - -
SFC 30 0.80 0.44
Presence 1 1 (100.0) - -
Absence 29 20 (69.0) 8 (27.6) 1 (3.4)
Smoking 30 0.81 0.41
Presence 8 6 (75.0) 2 (25.0) -
Absence 22 15 (68.2) 6 (27.3) 1 (4.5)
Appendectomy 30 <0.0001 20.60
Presence - - - -
Absence 30 21 (70.0) 8 (26.7) 1 (3.3)
EIM 30 0.60 1.03
Presence 17 11 (64.7) 5 (29.4) 1 (5.9)
Absence 13 10 (76.9) 3 (23.1) -
Surgery 30 0.37 1.98
Presence 26 17 (65.4) 8 (30.8) 1 (3.8)
Absence 4 4 (100.0) - -
(SFC: Similar familial cases; EIM: Extra intestinal manifestations; N: Total
number; CC: wild type IL23R L310P, CT: IL23R L310P heterozygous variant,
TT: IL23R L310P homozygous variant).
Table 7 Genotypic and allelic frequencies for the
ATG16L1 of UC patients and controls




OR (0.95 CI) P value
AA 11 (36.7.) 30 (26.1) 1.0
AG 15 (50.0) 76 (66.1) 0.54 (0.22-1.30) 0.17
GG 4 (13.3) 9 (7.8) 1.21 (0.31-4.75) 0.78
A 37 (61.7) 136 (59.1) 1.0
G 23 (38.3) 94 (40.9) 0.90 (0.50-1.61) 0.72
(AA: wild type ATG16L1 T300A, AG: ATG16L1 T300A heterozygous variant, GG:
ATG16L1 T300A homozygous variant; N: Total number; OR: odd ratio; CI
confidence interval; P: (P < 0.05)).
Table 8 Genotypic and allelic frequencies for the IL23R of
UC patients and controls




OR (0.95 CI) P value
CC 21 (70.0) 98 (85.2) 1.0
CT 8 (26.7) 14 (12.2) 2.67 (0.99-7.16) 0.05
TT 1 (3.3) 3 (2.6) 1.56 (0.15-15.70) 0.71
C 50 (83.3) 210 (91.3) 1.0
T 10 (16.7) 20 (8.7) 2.10 (0.92-4.77) 0.08
CC: wild type IL23R L310P, CT: IL23R L310P heterozygous variant, TT: IL23R
L310P homozygous variant; N: Total number; OR: odd ratio; CI confidence
interval; P: (P < 0.05).
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with early-onset disease in a Scottish cohort.
Regarding UC, a protective effect of this polymorphism
was identified. At present, it can only be speculated how
ATG16L1 T300A variant may confers risk or protection
from infection, depending on the nature of the pathogen
and the typical duration of infection. The cellular expres-
sion of ATG16L1 facilitates bacterial invasion, however the
IBD-associated ATG16L1 T300A variant may be protective
against bacterial infection.
Messer et al. demonstrated that Intestinal epithelial cells
somatically targeted to express the ATG16L1 T300A variant
show protection against invasion by Salmonella [23].IL23R polymorphism
The IL23R gene is another potential candidate gene for
CD risk [2,35]. IL-23R interacts with IL-23, which is a
cytokine that orchestrates intestinal inflammation via mul-
tiple pathways. It regulates the activity of immune cells
and plays an important role in the inflammatory response
against infection by bacteria and viruses [36]. The IL-23-
IL17 axis is a key pathogenic mechanism that mediates
the development and progress of inflammation by Th-17
cells. The role of the IL23-IL17 axis in IBD was supported
in human patients and animal models of colitis [37-39].
Similarly, several studies have pinpointed IL23 receptor as
a key pathway in the pathogenesis of inflammatory bowel
disease. It was confirmed by the genetic association of sev-
eral SNPs throughout the IL23R gene with CD and UC
[21,22,24-27,30,32,40-43].
It was hypothesized that IL23R gene variants have a dif-
ferential effect on Th17 cells with increased Th17 cytokine
secretion in patients with CD-associated IL23R variants
and decreased cytokine secretion in patients with CD-
protective IL23R variants [44].
In the present study, carriage of the variant allele was
associated with a protective effect for CD patients, simi-
larly to previously reported studies [45,46]. We further
analyzed whether the risk factor in the IL23R gene was
also shared by UC patients and did not detect a signifi-
cant association. Our subgroup analyses are likely
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lationship. This result confirms previous studies on
Italian [47] and North American populations [42].
Conclusion
In summary, the present study seems to indicate that
ATG16L1 plays an important role in CD behaviour and
confers protection for UC. In addition, IL23R gene showed
a protective effect for individuals with the TT genotype
and T allele against the development of Crohn’s disease.
Therefore, our results could reinforce the notion of a
different relevance of ATG16L1 and IL23R in the patho-
genesis of IBD in patients of different ethnic origin, with
a limited role in the Moroccan population. Due to small
sample size, an association cannot be ruled out. Further
studies in larger groups would be required to confirm
these findings.
Additional file
Additional file 1: Table S1. Clinical and epidemiological parameters of
control group.
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